Home › Funds › Squadron Capital Management LLC › CCCC
Squadron Capital Management LLC position in CCCC
C4 THERAPEUTICS INC · Health Care
Squadron Capital Management LLC reported holding 400,000 shares of CCCC (C4 THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$1.9M, representing 0.73% of its reported portfolio and ranking #29 among its reported holdings. Squadron Capital Management LLC has disclosed CCCC holdings in 2 of the last 2 reported quarters, going back to Q1 2026.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Squadron Capital Management LLC's CCCC position evolved
Squadron Capital Management LLC first disclosed a stake in CCCC in Q1 2026 at 2,250,000 shares (US$5.9M). Across 2 filings, Squadron Capital Management LLC increased the stake 0 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 400,000 shares valued at US$1.9M — a reduction of -1,850,000 shares quarter over quarter.. Notable position changes include a 82% trim in Q2 2026 (shares fell 29% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2026 | 2.25M | $5.92M | New |
| Q2 2026 | 400.00K | $1.87M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About CCCC and 13F data
CCCC (C4 THERAPEUTICS INC) is a Health Care company. 51 other funds we track also report a position in CCCC — the largest reported positions include RA CAPITAL MANAGEMENT, L.P. (US$37.4M), Lynx1 Capital Management LP (US$34.2M), Bain Capital Life Sciences Investors, LLC (US$33.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding CCCC
- RA CAPITAL MANAGEMENT, L.P. 8.00M sh · $37.36M · Q2 2026
- Lynx1 Capital Management LP 7.33M sh · $34.22M · Q2 2026
- Bain Capital Life Sciences Investors, LLC 7.17M sh · $33.49M · Q2 2026
- Soleus Capital Management, L.P. 3.38M sh · $15.78M · Q2 2026
- SILVERARC CAPITAL MANAGEMENT, LLC 3.03M sh · $14.16M · Q2 2026
- Ikarian Capital, LLC 2.43M sh · $11.36M · Q2 2026
- Patient Square Capital LP 1.61M sh · $7.51M · Q2 2026
- HighVista Strategies LLC 1.35M sh · $6.30M · Q2 2026
- Velan Capital Investment Management LP 570.00K sh · $2.66M · Q2 2026
- Seven Fleet Capital Management LP 381.17K sh · $1.78M · Q2 2026
More on Squadron Capital Management LLC
FAQ
How long has Squadron Capital Management LLC held CCCC?
Squadron Capital Management LLC has disclosed CCCC holdings in 2 of the last 2 reported quarters, going back to Q1 2026.
What is Squadron Capital Management LLC's current position in CCCC?
As of Q2 2026, Squadron Capital Management LLC holds 400.00K shares of CCCC (C4 THERAPEUTICS INC), valued at $1.87M, representing 0.73% of its reported portfolio and ranking #29.
Has Squadron Capital Management LLC been buying or selling CCCC?
In the latest 13F filing (Q2 2026), Squadron Capital Management LLC reduced its position in CCCC.
Which other funds hold CCCC?
Other major institutional holders of CCCC include RA CAPITAL MANAGEMENT, L.P., Lynx1 Capital Management LP, Bain Capital Life Sciences Investors, LLC, among 51 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.